CG Oncology
NASDAQ: CGONIncorporated in Delaware · 9 known investors
Find your way into CG Oncology
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer. The company's approach combines engineered viral immunotherapy with potential combination therapies to improve patient quality of life.
Founders & leadership
AK
Arthur KuaninChairman and CEOArthur Kuan is Chairman, President and Chief Executive Officer of CG Oncology, which develops oncolytic immunotherapy for urologic cancer.
Investors · 9
Funding
SEC filings, press & company announcements- Undisclosed amountSeries ENov 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does CG Oncology do?
- CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer. The company's approach combines engineered viral immunotherapy with potential combination therapies to improve patient quality of life.
- Who are CG Oncology's investors?
- CG Oncology's investors include Decheng Capital, Foresite Capital, Longitude Capital, Palm Drive Capital, RA Capital, TCG Crossover, ACORN BIOVENTURES, Ally Bridge Group and 1 more.